The issued patents cover the class of selective 5-HT compounds of Suven that are being developed to treat cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
Suven CEO Venkat Jasti said they are very pleased by the grant of these patents to Suven for their pipeline of molecules in CNS arena that are being developed for cognitive disorders.